Introduction
Extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases (AmpCs) are important mechanisms of resistance among Enterobacteriaceae. Infections caused by ESBL and /or AmpC-positive bacteria are of particular clinical and epidemiological importance and cause higher patient morbidity and mortality. 1, 2 ESBLs are typically plasmid-mediated, clavulanate susceptible enzymes that hydrolyze penicillins, extendedspectrum cephalosporins and aztreonam. AmpCs are cephalosporinases that are poorly inhibited by clavulanic acid. They can be differentiated from ESBLs by their ability to hydrolyze cephamycins as well as other extendedspectrum cephalosporins. AmpCs were presumed to be chromosomally mediated but since the late 1980s they have disseminated on plasmids and now represent a substantial clinical threat. The emergence and spread of pAmpCs in Enterobacteriaceae has made their detection clinically relevant, particularly in bacterial species naturally lacking chromosomal cephalosporinase namely in E.coli, Klebsiella spp. and Proteus mirabilis. Detection a pAmpC in a strain with a coexisting ESBL is even more challenging.
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. Moreover, AmpCs can interfere with ESBL detection particularly when using the current CLSI ESBL confirmatory tests. Resulting failures to detect ESBLs can endanger patients because false susceptibility to cephalosporins may be reported. 4 This warrants the need foran alternative ESBL confirmatory test of greater accuracy for AmpC-producing isolates. 5 At present, there are no guidelines or standardized phenotypic methods recommended for detection of AmpCs, though several methods have been described, including disc synergy assays using Amp-C inhibitors, a specific E test format for AmpC testing and a three-dimensional test. However, these methods are expensive, tedious and have not been systematically compared. 6, 7 This prospective study was designed and conducted at in the Central Microbiology Laboratory of Ain Shams University Hospital in Egypt to (a) determine the prevalence of ESBLs and AmpC-producers among bacterial isolates with reduced susceptibility to extended spectrum cephalosporines and cephamycins of Klebsiellae, (b) to evaluate the efficacy of the modified double disc synergy test (MDDST) as confirmatory ESBL tests in AmpC-positive isolates and (c) to assess the performance characteristics of phenotypic tests compared to the PCR as a gold standard test for the rapid and accurate detection ofAmpCs in ESBL-positive and ESBL-negative isolates.
Experimental Bacterial isolates
This study was done on 100 clinical isolates of Klebsiella spp. isolated from different clinical specimens referred to Microbiology Central Laboratory of Ain Shams University Hospitals Cairo, Egypt, for routine culture and sensitivity, from ICU, during a period of 3 months, from September to December 2015.
All Isolates have been subjected to the following tests: To screen for ESBLs production by disc diffusion method, 8 rd generation cephalosporin that is ceftazidime, cefotaxime, cefopodixime and cefepime, 9 a disc of AMC (20 μg amoxicillin + 10 μg clavulanic acid) and discs of CAZ, CTX, FEP and CPD were placed around AMC disc with a distance of 20 mm. Clear extension of the edge of the inhibition zone of cephalosporin toward the AMC disc shows positive result and interpreted as positive for ESBL production ( Figure ESI  1) . Negative result showed that no synergy is present ( Figure ESI 2) . To detect production of ESBLs by modified double disc synergy using FEP disc and piperacillin/tazobactam disc 10 a disc of TZP (piperacillin /tazobactam) (100/10 µg) was placed from FEP (30 μg) disc at a distance of 20 mm from it (centre to centre). Clear extension of the edge of the inhibition zone of FEP disc toward the TZP disc indicates a positive result and was interpreted as positive for ESBL production ( Figure ESI3 ). Negative results showed that there is no synergy ( Figure  ESI4 ).
CLSI method using ceftazidime/ ceftazidime-clavulanate (CAZ-CLA) E-test ESBL strips. 8 The E-test ESBL strip is a plastic drug-impregnated strip, one end of which generates a stable concentration gradient of ceftazidime (MIC test range, 0.5-32 mg L -1 ) and the remaining end of which generates a gradient of ceftazidime (MIC test range, 0.064-4 mg L -1 ) plus 4 mg L -1 clavulanic acid. The MIC value was read from the scale in terms of g mL -1 where the ellipse edge intersects the strip. ESBL production is inferred if the MIC ratio for cephalosporin alone/cephalosporin plus clavulanate MIC is ≥ 8 ( Figure ESI5 ). ESBL production was also identified by the presence of a phantom zone or a deformation of the CAZ inhibition zone independent of the MIC ratios ( When MIC values were above the test device range, interpretation was 'non-determinable'.Screening for AmpC production by resistance to cefoxitin disc (30 µg). 9 The antibiotic disc used FOX (30 µg) was allowed to diffuse into the medium and interact in a plate freshly seeded with the test organisms making zones of inhibition that have been measured and interpreted according to CLSI 8 interpretive criteria for screening of AmpC. Isolates showing diameter zone of inhibition ≤ 14mm were considered resistant ( Figure ESI6 . 11 Isolates showing diameter zone of inhibition > 14mm were considered sensitive ( Figure ESI7 ).
Confirmation of production of AmpC was done by modified three-dimensional test.
12 This test detects the tested isolate which produce AmpC -lactamase enzyme that isresistant to cefoxitin resulting in distortion of zone of inhibition of cefoxitin which is formed by E. coli ATCC 25922. Enhanced growth of the surface of the organism at the point where the slit intersected the zone of inhibition means a a positive result and is interpreted as evidence for the presence of AmpC β-lactamase ( Figure ESI8 . Isolates with no distortion are viewed as negative result and are recorded as non-AmpC producers ( Figure ESI9 ).
Real-time PCR

DNA extraction
Cells were harvested in a microcentrifuge tube by centrifuging for 10 min at 5000 x g (7500 rpm). The supernatant liquid was discarded. Washing was done twice with Tris-EDTA buffer by centrifugation at 8000 rpm for 10 min. 20 µL proteinase K and 200 µL Buffer AL were added. Mixing was done thoroughly by vortexing and incubation was done at 56 C for 20 min. 200 µL ethanol (96-100%) was added. Mixing was done thoroughly by vortexing. The mixture (including any precipitate) was pipetted into the DNA Mini spin column placed in a 2 mL collection tube. Centrifugation was done at ≥ 6000 x g (8000 rpm) for 1 min. Flow-through and collection tube were discarded. The DNA Mini spin column was placed in a new 2 mL collection tube. 500 µL Buffer AW1 was added and centrifugation was done for 1 min at ≥ 6000 x g (8000 rpm). Flow-through and collection tube were discarded. The DNA Mini spin column was placed in a new 2 mL collection tube. 500 µL Buffer AW2 was added followed by centrifugation for 3 min at 20,000xg (14,000 rpm) to dry the DNA membrane. Flowthrough and collection tube were discarded. The DNA Mini spin column was placed in a clean 1.5 or 2 mL micro centrifuge tube, and 100 µL Buffer AE was pipetted directly onto the DNA membrane. Incubation was done at room temperature for 1 min, and then centrifugation for 1min at ≥ 6000 x g (8000 rpm) to elute.
DNA amplification and detection
Reaction set-up
All solutions after thawing were gently vortexed and briefly centrifuged. A reaction master mix was prepared by adding the following components for each 25 μL reaction to a tube at room temperature (Table 1) . The primers used were:
FOXMF: 5´AAC ATG GGG TAT CAG GGA GAT G 3´.
FOXMR: 5´CAA AGC GCG TAA CCG GAT TGG 3´. 13 The master mix was mixed thoroughly and the appropriate volumes were dispensed into PCR tubes. The template DNA (≤ 500 ng/reaction) was added to the individual PCR tubes containing the master mix. Then the reaction mixture was mixed gently without creating bubbles (not to be vortexed) then centrifuged briefly (bubbles will interfere with fluorescence detection). The thermal cycler was programmed according to the recommendations below, then the samples were placed in the cycler and we started the program. Data was taken during the extension step. Thermal cycling conditions are given Table 2. 14 The amplification program was followed immediately by a melt program consisting of 1 min at 95 °C, 30 sec at 55 °C then again to 95 °C for 30 s.
The greenish horizontal line in the graph (Figure 3 ) is the threshold line at which the fluorescence begins to be detected (The point at which the amplification plot crosses the threshold is the cycle threshold = Ct). 15 The Tm of samples which were identical or close to that of positive control were considered the gene of target as shown in Figure 4 . 
Results
Fifty eight out of 100 isolates were AmpC producers by PCR (golden standard test). Fifty six out of 58 isolates that were positive by PCR test were resistant to FOX with a sensitivity of 96.6 % and specificity of 52.4 % for detection of AmpC production with positive predictive value and negative predictive value of (73.7 % and 91.7 %) respectively. There was moderate agreement between the results of both tests ( Thirty out of 58 AmpC producers were ESBL positive by E-test and MDDST with a sensitivity and specificity of 100 % in detection of ESBL in the presence of AmpC (Table 4) . While 23/58 were positive by DDST showing 76.7 % sensitivity and 100 % specificity for detection of ESBL in presence of AmpC with positive predictive value and negative predictive value of (100 % and 80 %) respectively (Table 5 ). There was substantial agreement between results of both the tests. Forty-two out of 100 isolates were negative Ampc by PCR test. Thirty two out of 42 clinical isolates were positive ESBL by both E-test and MDDST showing (100 %) sensitivity and specificity in detection of ESBL in absence of AmpC (Table 6 ). While, 29/42 (69.05 %) were positive by DDST showing 90.6 % sensitivity and 100% specificity of detection of ESBL in absence of AmpC. The positive predictive value and negative predictive value was (100 % and 76.9 %) respectively (Table 7) . There is a substantial agreement between results of both the tests. 
Discussion
The importance of detecting AmpC-producing isolates is highlighted by data showing high clinical failure rates when AmpC-producing strains of K. pneumoniae are treated with cephalosporin agents or the subsequent development of antibiotic resistance in such strains. 16 By antibiotic susceptibility testing it might be difficult to distinguish ESBL-producing organisms from plasmid AmpC-producing organisms because of their similar resistance. Distinguishing between AmpC-and ESBLproducing organisms has epidemiological significance and has therapeutic importance as well. In Egypt, one study assessed AmpC production among Enterobacteriaceae, 18 however, molecular techniques were not attempted. So, little is known about the genetic background of AmpC-producing isolates in Egypt.
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Results of the present study showed that the prevalence of ampC genes in 58/100 isolates of the selected species was 30/58(51.7%) whereas ESBL-producers were detected. AmpC prevalence was lower than that reported by ElHefnawy 18 from Egypt (34 % in 50 K. pneumoniae and E. coli isolates), but it was equivocal with another study from Singapore (26 % in 255 clinical isolates of E. coli, Klebsiella spp. and P. mirabilis). In the first study, molecular techniques were not attempted and they used one phenotypic test, the three dimensional test (TDT), while in the second study both TDT and the multiplex PCR were used. 19 These results were much higher than those reported in other parts of the world; in Spain (0.43%), 20 in China (2.79 %) 21 and in USA (3.3 %). 22 This may be due to the differences in the study population and the epidemiological differences in various geographic regions.
The high prevalence of AmpC producers in our study could be explained by 2 points: First, the prevalence of ESBL-production was high (62 %) and many of our ampCpositive isolates were also ESBLproducers30/58 (51.7 %). Previous Egyptian studies have also reported the high prevalence of ESBLs in Egypt;38 %, 23 61 % 24 and 65.8 %. 25 It has been recently found that infection with pAmpCproduceris frequently associated with a high copresencerate of ESBLs. 17 Second, our specimens were collected from patients admitted to ICU, it could be expected that they have been exposed to previous cephalosporin therapy whether empirically or according to the hospital antibiotic policy or due to unjustified courses as reported in a previous Egyptian study by El-Kholy. 23 Knowing that selective-pressure produced by the extensive use of oxyimino-cephalosporins are among the driving forces of increasing the prevalence of AmpC-production, 17 the high rate of AmpC production could be anticipated.
In our study 30/58 (51.7%) of the isolates were both AmpC and ESBL-positive by molecular detection methods. This rate was higher than that reported from western parts of the world: 7/117 (6%) in Spain, 20 4/81 (4.9 %) in Minnesota in USA. 26 Interestingly, 58/62 (93.5 %) of our ESBLpositive Klebsiella spp. was AmpC-positive. This rate is comparable with that reported in India as Vandana and Honnavar 27 detected AmpC in 39/52 (75 %) of ESBLproducing isolates of K.pneumoniae. As both ESBL and AmpC β-lactamases may coexist, therefore their detection is difficult because they mask each other. In the present study, all 30 ESBLproducers in AmpC-positive isolates were successfully identified by using the MDDST, in which FEP and TZP were utilized in approximation, implying that the use of this phenotypic method could overcome the masking effect of AmpC on phenotypicdetection of ESBLs. Similar observation has been reported by Khan 9 and Fam and ElDamarawy. 25 Use of a cefoxitin disk is useful in screening for AmpC but it is non-specific. In our study only 58/64 of cefoxitinresistant isolates had ampC genes. Several factors may explain resistance to cefoxitin in the AmpC-negative isolates: First, it may arise due to porin channel alterations and mutations as previously reported in Klebsiella spp. isolates. 3, 16 Second, cefoxitin-resistance phenotype in Klebsiella spp. can result from over expression of the chromosomal ampC gene due to mutations in the promoter or/and attenuator regions resulting in alterations in the permeability of the cell to cefoxitin or a combination of all thesefactors. 26 Third, cefoxitin has been demostrated as a substrate to active efflux pump in clinical isolates. 27 In conclusion, this study has revealed the occurrence of plasmid mediated AmpC beta-lactamase producing strains in clinically important bacterial isolates for the first time in our region. ESBL production may mask the phenotypic detection of pAmpC enzymes. MDDST is a simple and reliable method serve as reliable confirmatory tests for detection of ESBLs in AmpC positive isolates. Occurrence of a large percentage of multidrug resistant strains has been observed. As AmpC beta-lactamase production is frequently accompanied by multidrug resistance, so conjugative dissemination of this AmpC beta -lactamase encoding plasmids may facilitate the spread of resistance against a wide range of antibiotics among different members of Enterobacteriaceae. Imipenem is superior to other antibiotics for the treatment of serious infections due to AmpC beta-lactamase-producing enterobacteria.
